Table 2 Prior chemotherapy, dc vaccine results, and first chemotherapy after dc vaccine, per patient
Patient | Disease burden at day -35 | Prior chemotherapy | Response at day 56 | PFS (months) | OS (months) | First treatment after DC vaccine |
|---|---|---|---|---|---|---|
1 | Metastatic | Gemcitabine +/- trametinib | PD | 3.0 | 5.3 | None |
2 | Metastatic | Gemcitabine FOLFIRINOX | Not done | 2.1 | 2.1 | None |
3 | Metastatic | Gemcitabine + nab-paclitaxel Capecitabine with radiation erlotinib FOLFIRINOX | Not done | 1.8 | 2.1 | None |
4 | Metastatic | Gemcitabine + nab-paclitaxel Capecitabine with radiation FOLFIRINOX | PD | 3.0 | 6.3 | ABC294640a |
5 | Metastatic | Gemcitabine +/- ganitumab Gemcitabine + nab-paclitaxel | SD | 4.6 | 13.0 | Gemcitabine + nab-paclitaxel |
6 | Metastatic | FOLFIRINOX capecitabine with radiation | PD | 3.0 | 9.8 | FOLFIRINOX |
8 | Locally advanced | Gemcitabine + nab-paclitaxel capecitabine with radiation | Not done | 1.9 | 1.9 | None |
9 | Metastatic | FOLFIRINOX gemcitabine + nab-paclitaxel | not done | 2.3 | 2.3 | None |
10 | Locally advanced | FOLFIRINOX capecitabine with radiation | SD | 8.3 | 13.1 | Gemcitabine + nab-paclitaxel |
11 | Metastatic | FOLFIRINOX capecitabine | SD | 4.6 | 9.1 | Gemcitabine + nab-paclitaxel |
12 | Metastatic | Gemcitabine + nab-paclitaxel + ODSHb | PD | 3.0 | 10.1 | None |
13 | Locally advanced | FOLFIRINOX Capecitabine with radiation | SD | 34.3 | 34.3 | Gemcitabine + nab-paclitaxel |